指南与共识腹部泌尿生殖技术与安全CTMRPET

美国放射学会偶发发现委员会偶发淋巴结管理建议的单中心评估

The American College of Radiology Incidental Findings Committee Recommendations for Management of Incidental Lymph Nodes: A Single-Center Evaluation.
指南 / 共识 · Acad Radiol · 2017-02-03

单中心评估59枚符合ACR-IFC偶发淋巴结标准的腹盆部淋巴结,8.5%为恶性、91.5%为良性;ACR-IFC影像特征未能鉴别良恶性(P=0.164-1.0),且按建议的3个月初始随访时稳定的淋巴结偶可证实为恶性或后续缩小,作者认为可能需要细化影像标准并结合其他临床标准来优化随访。

要点

  • ACR-IFC影像特征将绝大多数偶发腹盆部淋巴结判为异常(两名阅片者分别为96.6%-98.3%具有≥1项可疑特征),但未能鉴别良恶性(P=0.164-1.0)。
  • 按ACR-IFC建议的3个月初始随访时稳定的淋巴结,偶可证实为恶性或在后续影像上缩小。
  • 6枚恶性淋巴结中2枚在3至<6个月随访时稳定,5枚恶性淋巴结中4枚的诊断得益于后续出现的结外肿瘤部位。

核心结论

  • ACR-IFC影像特征绝大多数将偶发淋巴结判为异常,但未能鉴别良恶性;按建议的3个月初始随访时稳定的淋巴结偶可证实为恶性或后续缩小,作者认为细化影像标准以界定特别高风险淋巴结并结合其他临床标准,可能有助于优化偶发腹盆部淋巴结的随访。

研究设计与样本

  • 单中心评估ACR-IFC关于偶发腹盆部异常淋巴结定义与随访建议的研究,共纳入59枚符合ACR-IFC偶发标准(无恶性肿瘤或淋巴增殖性疾病)且随访足以分类为良性或恶性的淋巴结;由两名放射科医师独立按ACR-IFC标准评估可疑特征。

关键影像表现/征象

  • 恶性淋巴结占8.5%,良性占91.5%。
  • 两名阅片者中分别有96.6%-98.3%的淋巴结具有≥1项可疑特征。
  • 88.1%-93.2%的淋巴结存在≥3枚淋巴结聚集。
  • 任何淋巴结均未发现坏死和血供丰富。
  • 任何ACR-IFC特征均未能鉴别良恶性淋巴结(P=0.164-1.0)。

诊断标准与关键数值

  • ACR-IFC可疑特征包括:圆形且肾门不清、血供丰富、坏死、≥3枚淋巴结聚集、≥2个区域各有≥2枚淋巴结聚集、腹膜后淋巴结≥1 cm。
  • 良性分类依据:活检、体积缩小或≥12个月稳定;恶性分类依据:活检,或发现原发恶性肿瘤合并氟脱氧葡萄糖高代谢或淋巴结增大。
  • 6枚恶性淋巴结中2枚在3至<6个月随访时稳定后才诊断;5枚恶性淋巴结中4枚的诊断得益于后续出现的结外肿瘤部位。
  • 按随访时间判定良性者:<3个月缩小13枚、3-5个月缩小5枚、6-11个月缩小8枚、≥12个月缩小9枚。

临床应用与阅片要点

  • 阅片时按ACR-IFC标准评估偶发腹盆部淋巴结,注意圆形且肾门不清、血供丰富、坏死、淋巴结聚集及腹膜后≥1 cm等特征。
  • ACR-IFC建议初始3个月随访;本研究显示该时间点稳定的淋巴结仍偶可证实为恶性或后续缩小。
  • 作者认为细化影像标准以界定特别高风险淋巴结并结合其他临床标准,可能有助于优化偶发腹盆部淋巴结的随访。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To assess the American College of Radiology Incidental Findings Committee's (ACR-IFC) recommendations for defining and following up abnormal incidental abdominopelvic lymph nodes.

MATERIALS AND METHODS: A total of 59 lymph nodes satisfying ACR-IFC criteria as incidental (no malignancy or lymphoproliferative disorder) and with sufficient follow-up to classify as benign (biopsy, decreased size, ≥12-month stability) or malignant (biopsy, detection of primary malignancy combined with either fluorodeoxyglucose hyperactivity or increase in size of the node) were included. Two radiologists independently assessed nodes for suspicious features by ACR-IFC criteria (round with indistinct hilum, hypervascularity, necrosis, cluster ≥3 nodes, cluster ≥2 nodes in ≥2 stations, size ≥1 cm in retroperitoneum). Outcomes were assessed with attention to ACR-IFC's recommendation for initial 3-month follow-up.

RESULTS: A total of 8.5% of nodes were malignant; 91.5% were benign. Two of six malignant nodes were stable at 3 to <6-month follow-up before diagnosis; diagnosis of four of five malignant nodes was facilitated by later development of non-nodal sites of tumor. A total of 13, 5, 8, and 9 nodes were deemed benign given a decrease at <3 months, 3-5 months, 6-11 months, or ≥12 months of follow-up. No ACR-IFC feature differentiated benign and malignant nodes (P = 0.164-1.0). A cluster ≥3 nodes was present in 88.1%-93.2% of nodes. A total of 96.6%-98.3% had ≥1 suspicious feature for both readers. Necrosis and hypervascularity were not identified in any node.

CONCLUSIONS: ACR-IFC imaging features overwhelmingly classified incidental nodes as abnormal, although did not differentiate benign and malignant nodes. Nodes stable at the ACR-IFC's advised initial 3-month follow-up were occasionally proven malignant or decreased on further imaging. Refinement of imaging criteria to define nodes of particularly high risk, integrated with other clinical criteria, may help optimize the follow-up of incidental abdominopelvic lymph nodes.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Smereka P, Doshi AM, Ream JM, et al. The American College of Radiology Incidental Findings Committee Recommendations for Management of Incidental Lymph Nodes: A Single-Center Evaluation. Acad Radiol. 2017. PMID: 28169142. doi:10.1016/j.acra.2016.12.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。